Stage III Cutaneous Melanoma AJCC v7 Completed Phase 2 Trials for Aldesleukin (DB00041)

Indication	Status	Phase
DBCOND0091046 (Stage III Cutaneous Melanoma AJCC v7)	Completed	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT01807182	Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma	Treatment	Aldesleukin (DB00041) Cyclophosphamide (DB00531) Fludarabine (DB01073)
NCT01258855	Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery	Treatment	Aflibercept (DB08885) Aldesleukin (DB00041)